Product Description: Azintuxizumab (ABBV-383; PR-1471272) is an IgG4 T cell-engaging bispecific mAb (T-BsAb) targeting B cell maturation antigen (BCMA). Azintuxizumab has the potential to be used in relapsed/refractory multiple myeloma (RRMM) research. Azintuxizumab is composed of two heavy chains and one light chain: the heavy chain (human CD319 antigen and human-mouse monoclonal PR-1471272, respectively) and the light chain (human-mouse monoclonal PR-1471272) are connected by disulfide bonds and can bind to CD3 (Kd=1.3 μM). Azintuxizumab can form ADC conjugates with derivatives of hemistarlin (HY-117371)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576-3586./[2]Hemiastarlin derivative and antibody-drug conjugates including same. World Intellectual Property Organization, WO2019031615 A1 2019-02-14 .
CAS Number: 1826819-57-1
Molecular Weight: N/A
Compound Purity: 99.0
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody;CD3
English
Deutsch
